Federated Investors Inc. PA Has $414,000 Position in Revance Therapeutics Inc (RVNC)

Federated Investors Inc. PA held its stake in Revance Therapeutics Inc (NASDAQ:RVNC) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,000 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Federated Investors Inc. PA owned about 0.07% of Revance Therapeutics worth $414,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in RVNC. Rothschild Asset Management Inc. increased its stake in Revance Therapeutics by 2.6% in the third quarter. Rothschild Asset Management Inc. now owns 10,808 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 269 shares in the last quarter. Wells Fargo & Company MN increased its stake in Revance Therapeutics by 19.1% in the third quarter. Wells Fargo & Company MN now owns 10,987 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 1,759 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in shares of Revance Therapeutics by 5.3% in the third quarter. Essex Investment Management Co. LLC now owns 86,000 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 4,299 shares during the last quarter. Granite Investment Partners LLC acquired a new stake in shares of Revance Therapeutics during the third quarter valued at approximately $1,319,000. Finally, FineMark National Bank & Trust boosted its stake in shares of Revance Therapeutics by 750.0% in the third quarter. FineMark National Bank & Trust now owns 8,500 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 7,500 shares during the last quarter.

Revance Therapeutics Inc (NASDAQ:RVNC) traded down 0.602% during trading on Friday, hitting $20.625. 79,441 shares of the company traded hands. The firm’s market cap is $604.70 million. Revance Therapeutics Inc has a 52-week low of $12.35 and a 52-week high of $24.30. The company’s 50-day moving average is $20.11 and its 200 day moving average is $18.89.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Monday, February 27th. The biopharmaceutical company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.11. Revance Therapeutics had a negative net margin of 28,187.33% and a negative return on equity of 37.31%. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.07 million. During the same period in the prior year, the company earned ($0.83) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities analysts anticipate that Revance Therapeutics Inc will post ($3.62) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Federated Investors Inc. PA Has $414,000 Position in Revance Therapeutics Inc (RVNC)” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://transcriptdaily.com/2017/04/22/federated-investors-inc-pa-has-414000-position-in-revance-therapeutics-inc-rvnc.html.

Several brokerages have commented on RVNC. Aegis set a $28.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Sunday, January 8th. Zacks Investment Research cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 12th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $33.83.

In other news, CEO L Daniel Browne sold 12,000 shares of the company’s stock in a transaction on Wednesday, January 25th. The stock was sold at an average price of $19.78, for a total transaction of $237,360.00. Following the completion of the sale, the chief executive officer now directly owns 184,627 shares of the company’s stock, valued at $3,651,922.06. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 31.15% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.